Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enoblituzumab - MacroGenics

Drug Profile

Enoblituzumab - MacroGenics

Alternative Names: Anti-B7-H3 mAb; MGA-271; TJ 271

Latest Information Update: 23 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Developer I-MAB Biopharma; MacroGenics; Masonic Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD276 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Bladder cancer; Fallopian tube cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer

Most Recent Events

  • 15 Apr 2024 I-MAb Biopharma withdraws the phase II Basket trial in Solid tumours (Late-stage disease, Combination therapy) in China (Injection), due to company development strategy adjustment (NCT05338580)
  • 04 Apr 2024 Discontinued - Phase-I for Fallopian tube cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV) as of April 2024 (MacroGenics pipeline, April 2024)
  • 04 Apr 2024 Discontinued - Phase-I for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Locally recurrent, Metastatic disease, Second-line therapy or greater) in USA (IV) as of April 2024 (MacroGenics pipeline, April 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top